Program
solizmestrocel
Also written as “human umbilical cord mesenchymal stem cells”, “Human umbilical cord mesenchymal stem cells” and “Human Umbilical Cord Mesenchymal Stem Cells Injection”.
Its studies are mostly in Liver Cirrhosis · Ischemic Stroke · Respiratory Distress Syndrome · Arthritis, Rheumatoid · Primary Ovarian Insufficiency, led by 22 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shenzhen Beike Bio-Technology | 60 open or running | phase 2since Apr 26, 2011 | Apr 26, 2011 | none ahead |
| Meridigen Biotech | 54 open or running | phase 1since Sep 17, 2019 | Sep 17, 2019 | none ahead |
| PT. Prodia Stem Cell Indonesia | 54 open or running | phase 2since Feb 20, 2020 | Feb 20, 2020 | Dec 2026phase 2 · NCT07439848 |
| Shenzhen Hornetcorn Bio-technology | 40 open or running | phase 1since Nov 3, 2014 | Nov 3, 2014 | none ahead |
| Asia Cell Therapeutics (Shanghai) | 33 open or running | phase 2since May 25, 2023 | May 25, 2023 | Dec 31, 2026phase 1 · NCT05962762 |
| Translational Biosciences | 30 open or running | phase 2since Oct 31, 2013 | Oct 31, 2013 | none ahead |
| Baylx | 21 open or running | phase 2since Jun 28, 2020 | Jan 30, 2019 | Dec 31, 2027phase 1 · NCT03828344 |
| alliancells-bioscience-corporation-limited | 10 open or running | phase 2since Feb 22, 2012 | Feb 22, 2012 | none ahead |
| asia-stem-cell-regenerative-pharmaceutical-co-ltd | 11 open or running | no phasesince Sep 19, 2021 | Sep 19, 2021 | none ahead |
| beijing-tuohua-weiye-biotechnology-co-ltd | 11 open or running | phase 2since Feb 2, 2026 | Feb 2, 2026 | Dec 31, 2026phase 2 · NCT07413549 |
| BOE Technology Group | 11 open or running | phase 1since May 22, 2026 | May 22, 2026 | Mar 30, 2028phase 1 · NCT07628933 |
| bright-cell-inc | 11 open or running | phase 1since Aug 6, 2022 | Aug 6, 2022 | Jan 9, 2028phase 1 · NCT05494723 |
| cellonis-biotechnology-co-ltd | 10 open or running | phase 1since Jun 10, 2010 | Jun 10, 2010 | none ahead |
| Cook Group | 11 open or running | phase 2since Aug 27, 2024 | Aug 27, 2024 | Oct 31, 2028phase 2 · NCT06579352 |
| cytopeutics-sdn-bhd | 10 open or running | phase 2since Nov 15, 2020 | Nov 15, 2020 | none ahead |
| Ever Supreme Bio Technology | 10 open or running | phase 1since May 5, 2020 | May 5, 2020 | none ahead |
| guangzhou-saliai-stem-cell-science-and-technology-co-ltd | 10 open or running | phase 2since Jul 30, 2017 | Jul 30, 2017 | none ahead |
| jiangsu-topcel-kh-pharmaceutical-co-ltd | 11 open or running | phase 2since Mar 1, 2026 | Mar 1, 2026 | Mar 30, 2027phase 2 · NCT07452822 |
| meribank-biotech-co-ltd | 11 open or running | phase 2since Jun 18, 2024 | Jun 18, 2024 | Dec 2026phase 2 · NCT06501066 |
| shandong-qilu-stem-cells-engineering-co-ltd | 10 open or running | phase 2since May 6, 2018 | May 6, 2018 | none ahead |
| shanghai-life-science-technology | 10 open or running | phase 1since Mar 28, 2019 | Mar 28, 2019 | none ahead |
| Shenzhen Wingor Biotechnology | 11 open or running | phase 2since Jul 27, 2026 | Jul 27, 2026 | Sep 30, 2028phase 2 · NCT07775391 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Jun 10, 2010.
- Aug 1, 2021Phase 2 study in Ischemic StrokePT. Prodia Stem Cell Indonesia · NCT05008588 · 15 enrolled · Indonesia
- Sep 19, 2021asia-stem-cell-regenerative-pharmaceutical-co-ltd's first study: no phase study in Liver CirrhosisNew to asia-stem-cell-regenerative-pharmaceutical-co-ltdasia-stem-cell-regenerative-pharmaceutical-co-ltd · NCT05106972 · 30 planned · China
- Aug 6, 2022bright-cell-inc's first study: phase 1 study in POINew to bright-cell-incbright-cell-inc · NCT05494723 · 6 planned
- May 25, 2023Asia Cell Therapeutics (Shanghai)'s first study: phase 1 study in Spondylitis, AnkylosingNew to Asia Cell Therapeutics (Shanghai)Asia Cell Therapeutics (Shanghai) · NCT05962762 · 9 planned
- May 25, 2023Phase 2 study in Decompensated Liver CirrhosisAsia Cell Therapeutics (Shanghai) · NCT05948982 · 18 planned
- Jun 28, 2023Phase 2 study in Respiratory Distress SyndromePT. Prodia Stem Cell Indonesia · NCT07439848 · 15 planned · Indonesia
- Jul 26, 2023Phase 1 study in Respiratory Distress SyndromeAsia Cell Therapeutics (Shanghai) · NCT05983627 · 9 planned
- Jun 18, 2024meribank-biotech-co-ltd's first study: phase 2 study in Pathologic ProcessesNew to meribank-biotech-co-ltdmeribank-biotech-co-ltd · NCT06501066 · 66 enrolled · Taiwan
- Aug 27, 2024Cook Group's first study: phase 2 study in Muscular Dystrophy, DuchenneNew to Cook GroupCook Group · NCT06579352 · 35 enrolled · United States
- Jul 7, 2025Phase 2 study in Diabetic NephropathiesPT. Prodia Stem Cell Indonesia · NCT07396155 · 10 planned · Indonesia
- Feb 2, 2026beijing-tuohua-weiye-biotechnology-co-ltd's first study: phase 2 study in Decompensated Hepatitis B CirrhosisNew to beijing-tuohua-weiye-biotechnology-co-ltdbeijing-tuohua-weiye-biotechnology-co-ltd · NCT07413549 · 76 planned · China
- Mar 1, 2026jiangsu-topcel-kh-pharmaceutical-co-ltd's first study: phase 2 study in Arteriovenous Fistula StenosisNew to jiangsu-topcel-kh-pharmaceutical-co-ltdjiangsu-topcel-kh-pharmaceutical-co-ltd · NCT07452822 · 54 planned
- May 22, 2026BOE Technology Group's first study: phase 1 study in Ischemic StrokeNew to BOE Technology GroupBOE Technology Group · NCT07628933 · 35 planned · China
- Jul 27, 2026Shenzhen Wingor Biotechnology's first study: phase 2 study in Primary Ovarian InsufficiencyNew to Shenzhen Wingor BiotechnologyShenzhen Wingor Biotechnology · NCT07775391 · 59 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Pathologic Processesmeribank-biotech-co-ltd · NCT06501066
- Dec 2026Primary completion: phase 2 study in Respiratory Distress SyndromePT. Prodia Stem Cell Indonesia · NCT07439848
- Dec 31, 2026Primary completion: phase 2 study in Decompensated Hepatitis B Cirrhosisbeijing-tuohua-weiye-biotechnology-co-ltd · NCT07413549
- Dec 31, 2026Primary completion: phase 1 study in Spondylitis, AnkylosingAsia Cell Therapeutics (Shanghai) · NCT05962762
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07775391Primary Ovarian Insufficiency · China | 2 | Recruiting | Shenzhen Wingor Biotechnology | Sep 30, 2028 | 59 |
| NCT07628933Ischemic Stroke · China | 1 | Not yet recruiting | BOE Technology Group | Mar 30, 2028 | 35 |
| NCT07452822Arteriovenous Fistula Stenosis | 2 | Not yet recruiting | jiangsu-topcel-kh-pharmaceutical-co-ltd | Mar 30, 2027 | 54 |
| NCT07413549Decompensated Hepatitis B Cirrhosis · China | 2 | Recruiting | beijing-tuohua-weiye-biotechnology-co-ltd | Dec 31, 2026 | 76 |
| NCT07396155Diabetic Nephropathies · Indonesia | 2 | Recruiting | PT. Prodia Stem Cell Indonesia | Jul 2027 | 10 |
| NCT06579352Muscular Dystrophy, Duchenne · United States | 2 | Active, not recruiting | Cook Group | Oct 31, 2028 | 35 |
| NCT06501066Pathologic Processes · Taiwan | 2 | Active, not recruiting | meribank-biotech-co-ltd | Dec 2026 | 66 |
| NCT05983627Respiratory Distress Syndrome | 1 | Not yet recruiting | Asia Cell Therapeutics (Shanghai) | Jun 30, 2025 | 9 |
| NCT07439848Respiratory Distress Syndrome · Indonesia | 2 | Recruiting | PT. Prodia Stem Cell Indonesia | Dec 2026 | 15 |
| NCT05962762Spondylitis, Ankylosing | 1 | Not yet recruiting | Asia Cell Therapeutics (Shanghai) | Dec 31, 2026 | 9 |
| NCT05948982Decompensated Liver Cirrhosis | 2 | Not yet recruiting | Asia Cell Therapeutics (Shanghai) | Dec 31, 2026 | 18 |
| NCT05494723POI | 1 | Not yet recruiting | bright-cell-inc | Jan 9, 2028 | 6 |
| NCT05106972Liver Cirrhosis · China | – | Recruiting | asia-stem-cell-regenerative-pharmaceutical-co-ltd | Dec 31, 2024 | 30 |
| NCT05008588Ischemic Stroke · Indonesia | 2 | Active, not recruiting | PT. Prodia Stem Cell Indonesia | Mar 2026 | 15 |
| NCT04914403Frailty · Taiwan | 1 | Recruiting | Meridigen Biotech | Dec 2024 | 6 |
| NCT04893174Osteoarthritis, Knee · Taiwan | 1 | Recruiting | Meridigen Biotech | Sep 2024 | 6 |
| NCT05016011Osteoarthritis, Knee · Malaysia | 2 | Completed | cytopeutics-sdn-bhd | Mar 21, 2022 | 28 |
| NCT04452097COVID-19 | 2 | Withdrawn | Baylx | Jul 1, 2027 | 0 |
| NCT04434768Stroke · Taiwan | 1 | Completed | Ever Supreme Bio Technology | Jan 23, 2026 | 10 |
| NCT04347967Respiratory Distress Syndrome · Taiwan | 1 | Not yet recruiting | Meridigen Biotech | Sep 2024 | 18 |
| NCT04315025Retinitis Pigmentosa · Indonesia | 2 | Completed | PT. Prodia Stem Cell Indonesia | Jun 20, 2019 | 18 |
| NCT04314687Cerebral Palsy · Indonesia | 2 | Active, not recruiting | PT. Prodia Stem Cell Indonesia | Jul 2026 | 78 |
| NCT04206007Pulmonary Disease, Chronic Obstructive · Taiwan | 1 | UNKNOWN | Meridigen Biotech | Dec 31, 2023 | 9 |
| NCT04097652Ischemic Stroke · Taiwan | 1 | Recruiting | Meridigen Biotech | Dec 31, 2023 | 9 |
| NCT03902067Ventricular Dysfunction, Left · China | 1 | Withdrawn | shanghai-life-science-technology | Dec 31, 2025 | 0 |
| NCT03828344Arthritis, Rheumatoid | 1 | Not yet recruiting | Baylx | Dec 31, 2027 | 16 |
| NCT03529136Decompensated Liver Cirrhosis | 2 | UNKNOWN | shandong-qilu-stem-cells-engineering-co-ltd | Dec 31, 2019 | 252 |
| NCT03237442Ocular Corneal Burn · China | 2 | UNKNOWN | guangzhou-saliai-stem-cell-science-and-technology-co-ltd | Dec 30, 2018 | 100 |
| NCT02790762Pneumoconiosis · China | 1 | UNKNOWN | Shenzhen Hornetcorn Bio-technology | Jun 2017 | 10 |
| NCT02652351Liver Cirrhosis · China | 1 | UNKNOWN | Shenzhen Hornetcorn Bio-technology | May 2016 | 20 |
| NCT02291926Cartilage Diseases · China | 1 | Completed | Shenzhen Hornetcorn Bio-technology | Jul 2016 | 20 |
| NCT02283879Cerebral Hemorrhage · China | 1 | UNKNOWN | Shenzhen Hornetcorn Bio-technology | Dec 2016 | 20 |
| NCT02192749Autistic Disorder · Panama | 2 | Completed | Translational Biosciences | Aug 2017 | 20 |
| NCT02034188Multiple Sclerosis · Panama | 2 | Completed | Translational Biosciences | Mar 2016 | 20 |
| NCT01985464Arthritis, Rheumatoid · Panama | 2 | UNKNOWN | Translational Biosciences | Dec 2019 | 20 |
| NCT01742533Primary Ovarian Insufficiency · China | 2 | UNKNOWN | Shenzhen Beike Bio-Technology | Jun 2013 | 40 |
| NCT01610440Muscular Dystrophy, Duchenne · China | 2 | UNKNOWN | Shenzhen Beike Bio-Technology | Mar 2013 | 15 |
| NCT01547091Arthritis, Rheumatoid · China | 2 | UNKNOWN | alliancells-bioscience-corporation-limited | Oct 2014 | 200 |
| NCT01443689Burns · China | 2 | UNKNOWN | Shenzhen Beike Bio-Technology | Mar 2013 | 20 |
| NCT01364246Multiple Sclerosis, Chronic Progressive · China | 2 | UNKNOWN | Shenzhen Beike Bio-Technology | Mar 2013 | 20 |
| NCT01360164Spinocerebellar Degenerations · China | 2 | UNKNOWN | Shenzhen Beike Bio-Technology | Dec 2012 | 20 |
| NCT01343511Autistic Disorder · China | 2 | Completed | Shenzhen Beike Bio-Technology | Jun 2010 | 37 |
| NCT01143168Diabetes Mellitus, Type 1 · China | 1 | UNKNOWN | cellonis-biotechnology-co-ltd | Aug 2011 | 24 |
How it is read
Names in the registry
- “human umbilical cord mesenchymal stem cells”, 6 entries
- “Human umbilical cord mesenchymal stem cells”, 4 entries
- “Human Umbilical Cord Mesenchymal Stem Cells Injection”, 3 entries
- “UC-MSC”, 3 entries
- “Umbilical Cord Mesenchymal Stem Cells”, 3 entries
Conditions, from the studies’ own filings
- Liver Cirrhosis, 4 studies
- Ischemic Stroke, 3 studies
- Respiratory Distress Syndrome, 3 studies
- Arthritis, Rheumatoid, 3 studies
- Primary Ovarian Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.